the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). It also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Melanoma circulating tumor cell (CTC) count (number of CTC/ml)
Timeframe: At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
Circulating microRNAs (copies/ml)
Timeframe: At enrollment and at every scheduled follow-up visits throughtout the study (24 months)